Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

Lignende værker

• Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
  af: Tang, Ning, et al.
  Udgivet: (2016)
• Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis
  af: Yuxi Ma, et al.
  Udgivet: (2025-06-01)
• Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
  af: Zhang, Shu, et al.
  Udgivet: (2016)
• Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
  af: Reck, Martin, et al.
  Udgivet: (2020)
• A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
  af: Wang H, et al.
  Udgivet: (2020-05-01)